Chapter 19 of 25
- Confirm recurrence and extent
- Consider local salvage if appropriate
- Choose systemic therapy using prior treatment and biomarkers
- Integrate symptom control and reassess goals
What you will learn
Understand when local salvage may be possible; compare systemic options; interpret pivotal trials without treating their averages as predictions.
First establish the pattern
A suspicious scan does not always prove recurrence. Biopsy is considered when feasible and useful, especially if another diagnosis or a new tumour is possible. The team reviews the original pathology, radiation fields and doses, operations, medicines and interval since treatment. A local recurrence without previous pelvic radiation may be treated with curative chemoradiation and brachytherapy. Selected central pelvic recurrences after radiation may be considered for pelvic exenteration at a specialist centre.
Exenteration is major surgery that may remove involved pelvic organs and require urinary or bowel diversion. It is only appropriate when complete removal appears feasible and the burdens are acceptable. Reirradiation, stereotactic radiation or surgery for limited metastases can be considered in selected cases; they are not routine solutions for every recurrence.
First-line systemic treatment
Platinum plus paclitaxel is a common backbone. Pembrolizumab can be added for appropriate PD-L1 CPS-positive disease under the relevant label, with bevacizumab considered when safe. Previous cisplatin during radiation, kidney function, neuropathy, symptoms and treatment interval help guide platinum choice. The KEYNOTE-826 population and results are explained in the immunotherapy chapter.
GOG-240 compared chemotherapy with or without bevacizumab in advanced disease. Its final 2017 analysis reported median overall survival of 16.8 versus 13.3 months, hazard ratio 0.77. Bevacizumab also increased important risks, including fistula, especially in previously irradiated tissue. Bleeding, poor wound healing, bowel involvement, uncontrolled hypertension and clotting risks must be considered; adding it is not automatic.
Later-line options and evidence
EMPOWER-Cervical 1 randomized 608 patients after platinum-containing treatment to cemiplimab or single-agent chemotherapy. The 2022 report showed median overall survival of 12.0 versus 8.5 months, hazard ratio 0.69. The EU indication covers progression on or after platinum chemotherapy without a PD-L1 requirement. Regional approval differs, and benefit from switching between checkpoint inhibitors after prior immunotherapy is not established by this trial.
Tisotumab vedotin is a tissue-factor-directed antibody-drug conjugate. The single-arm innovaTV 204 study showed an objective response in about 24% of 101 treated patients, but had no randomized comparator. The phase III innovaTV 301 trial compared it with chemotherapy after prior treatment: median overall survival was 11.5 versus 9.5 months, hazard ratio 0.70. It received regular US approval in 2024 after progression on or after chemotherapy. Eye protection, eye examinations, bleeding and neuropathy monitoring are essential.
Choosing a sequence and protecting quality of life
Options depend on prior checkpoint exposure, biomarkers, drug access, organ function, performance status and preferences. Single-agent chemotherapy, a suitable targeted option or a clinical trial may be considered. There is no universally best sequence for every patient, particularly after first-line immunotherapy. Ask what benefit is realistic, when response will be assessed and when a treatment should stop.
Palliative care can help with bleeding, pain, discharge, bowel or urinary obstruction, fatigue and family stress alongside anticancer treatment. Short-course radiation or procedures may relieve specific symptoms. Choosing symptom-focused care when treatment burdens exceed likely benefit is an active medical plan, not abandonment.
Misconception and common question
“All recurrence is treated the same way” is false. Can recurrent cancer ever be cured? Selected localized recurrences may have curative options; widespread disease is usually treated to control cancer and preserve quality of life.
Take-home messages
Bring the complete previous treatment record. Ask whether local salvage is possible before assuming only systemic therapy is available. Review benefits, toxicity, access and goals at each treatment change.
References and review status
- Tewari et al. GOG-240 final survival analysis, Lancet 2017
- Tewari et al. EMPOWER-Cervical 1, NEJM 2022
- EMA — Libtayo (cemiplimab), current authorized indications
- Coleman et al. innovaTV 204 phase II study, Lancet Oncology 2021
- Vergote et al. innovaTV 301 randomized phase III trial, NEJM 2024
- FDA — Tisotumab vedotin regular approval, April 2024
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy